Technical Analysis for NCNA - NuCana plc

Grade Last Price % Change Price Change
F 1.54 -4.94% -0.08
NCNA closed down 4.94 percent on Friday, November 1, 2024, on 9 percent of normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Nov 14
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Expansion Breakdown Bearish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%

   Recent Intraday Alerts

Alert Time
Down 3% about 22 hours ago
Fell Below Lower Bollinger Band about 22 hours ago
Fell Below Previous Day's Low about 22 hours ago
Down 2 % about 22 hours ago
Down 1% about 22 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

NuCana plc Description

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin, a novel nucleoside analog.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Health Sciences Treatment Of Cancer Drug Discovery Cancer Cell Solid Tumor Cancers Prodrugs Gemcitabine Organofluorides

Is NCNA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 19.41
52 Week Low 1.53
Average Volume 1,729,331
200-Day Moving Average 4.66
50-Day Moving Average 2.97
20-Day Moving Average 1.88
10-Day Moving Average 1.76
Average True Range 0.26
RSI (14) 33.33
ADX 9.17
+DI 22.70
-DI 32.26
Chandelier Exit (Long, 3 ATRs) 1.46
Chandelier Exit (Short, 3 ATRs) 2.30
Upper Bollinger Bands 2.22
Lower Bollinger Band 1.54
Percent B (%b) 0.0
BandWidth 35.77
MACD Line -0.33
MACD Signal Line -0.37
MACD Histogram 0.0415
Fundamentals Value
Market Cap 81.3 Million
Num Shares 52.8 Million
EPS -0.85
Price-to-Earnings (P/E) Ratio -1.81
Price-to-Sales 0.00
Price-to-Book 0.59
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.81
Resistance 3 (R3) 1.84 1.77 1.77
Resistance 2 (R2) 1.77 1.70 1.76 1.75
Resistance 1 (R1) 1.66 1.66 1.63 1.63 1.73
Pivot Point 1.59 1.59 1.58 1.58 1.59
Support 1 (S1) 1.48 1.52 1.45 1.45 1.35
Support 2 (S2) 1.41 1.48 1.40 1.33
Support 3 (S3) 1.30 1.41 1.32
Support 4 (S4) 1.27